Cushing’s syndrome (CS) causes metabolic abnormalities that determine an increased cardiovascular risk not only during the active phase of the disease but also for a long time after cure. Cardiovascular complications, such as premature atherosclerosis, coronary artery disease, heart failure, and stroke, in patients with CS cause a mortality rate higher than that observed in a normal population. The increased cardiovascular risk is mainly due to metabolic complications, such as metabolic syndrome, but also to vascular and cardiac alterations such as atherosclerosis and cardiac structural and functional changes. In the clinical management of patients with CS the focus should be on identifying the global cardiovascular risk and the aim should be to control not only hypertension but also other correlated risk factors, such as obesity, glucose intolerance, insulin resistance, dyslipidemia, endothelial dysfunction and the prothrombotic state. Considering that remission from hypercortisolism is often difficult to achieve and that the cardiovascular risk can persist even during disease remission, care and control of all cardiovascular risk factors should be one of the primary goals during the follow-up of these patients.

Keywords:
Cushing’s syndrome, Cushing’s disease, Cardiovascular disease, Cardiovascular risk, Cardiac abnormalities, Vascular abnormalities, Cardiac hypertrophy, Hypertension, Atherosclerosis, Metabolic syndrome
1.
Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A: Cushing’s syndrome. Endocrinol Metab Clin North Am 2008;37:135–149.
2.
Exabe J, Vazquez JA: Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994;4:479–484.
3.
Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J: Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117–123.
4.
Pivonello R, De Martino MC, De Leo M, Tauchmanovà L, Faggiano A, Lombardi G, Colao A: Cushing’s syndrome: aftermath of the cure. Arq Bras Endocrinol Metab 2007;51:1381–1391.
5.
Pivonello R, Faggiano A, Lombardi G, Colao A: The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 2005;34:327–339.
6.
Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide population. Endocrinol Metab Clin North Am 2004;33:351–375.
7.
Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A: Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003;88:2527–2533.
8.
Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G: Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999;84:2664–2672.
9.
Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, Pagnan A, Mantero F, Scaroni C: Patients with Cushing’s syndrome have increased intima-media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006;38:405–410.
10.
Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Kiriş A, Orem C, Celik S: Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s syndrome 2007;25:182–190.
11.
Ermetici F, Malavazos AE, Corbetta S, Eller-Vainicher C, Cannavò S, Corsi MM, Ambrosi B: Soluble adhesion molecule levels in patients with Cushing’s syndrome before and after cure. J Endocrinol Invest 2008;31:389–392.
12.
Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J: Biochemical markers for cardiovascular risk following treatment in endogenous Cushing’s syndrome. J Endocrinol Invest 2008;31:400–405.
13.
Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A: Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 2002;87:3662–3666.
14.
Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C: Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:3745–3751.
15.
Faggiano A, Melis D, Alfieri R, De Martino M, Filippella M, Milone F, Lombardi G, Colao A, Pivonello R: Sulfur amino acids in Cushing’s disease: insight homocysteine and taurine levels in patients with active and cured disease. J Clin Endocrinol Metab 2005;90:6616–6622.
16.
Magiakou MA, Smyrnaki P, Chrousos GP: Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 2006;20:467–482.
17.
Pecori Giraldi F, Toja PM, De Martin M, Maronati A, Scacchi M, Omboni S, Cavagnini F, Parati G: Circadian blood pressure profile in patients with active Cushing’s disease and after long-term cure. Horm Metab Res 2007;39:908–914.
18.
Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F: Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol 2003;41:2275–2279.
19.
Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA: Cardiac dysfunction is reserved upon successful treatment of Cushing’s syndrome. Eur J Endocrinol 2010;162:331–340.
20.
Fallo F, Maffei P, Dalla Pozza A, Carli M, Della Mea P, Lupia M, Rabbia F, Sonino N: Cardiovascular autonomic function in Cushing’s syndrome. J Endocrinol Invest 2009;32:41–45.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.